37656-48-7

Basic information

• Product Name: 4-(4-FLUORO-PHENYL)-PIPERIDINE
• Synonyms: 4-(4-FLUORO-PHENYL)-PIPERIDINE;4-(Fluoro-phenyl)-piperidine hydrochloride;Albb-005757;Piperidine, 4-(4-fluorophenyl)-
• CAS NO: 37656-48-7
• Molecular Formula: C₁₁H₁₄FN
• Molecular Weight: 179.23
• Mol File: 37656-48-7.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 258.6°Cat760mmHg
• Flash Point: 110.2°C
• Appearance: /
• Density: 1.048g/cm³
• Vapor Pressure: 0.0136mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.18±0.10(Predicted)
• CAS DataBase Reference: 4-(4-FLUORO-PHENYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-FLUORO-PHENYL)-PIPERIDINE(37656-48-7)
• EPA Substance Registry System: 4-(4-FLUORO-PHENYL)-PIPERIDINE(37656-48-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 37656-48-7(Hazardous Substances Data)

Usage

General Description

4-(4-Fluoro-phenyl)-piperidine is a chemical compound with the molecular formula C11H14FN. It is a piperidine derivative that contains a fluorophenyl group. 4-(4-FLUORO-PHENYL)-PIPERIDINE is often used in pharmaceutical research and drug development due to its potential interactions with the central nervous system. It has been studied for its potential as a potential analgesic and antipsychotic agent. Additionally, 4-(4-Fluoro-phenyl)-piperidine has also been investigated for its potential use in the development of new therapeutics for various neurological and psychiatric disorders. Its structure and properties make it an important tool for the design and synthesis of novel drugs with potential therapeutic applications.

InChI:InChI=1/C11H14FN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2

Upstream product

• 7440-05-3 palladium 
• 1978-61-6 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 183950-95-0 tert-butyl 4-(4'-fluorophenyl)piperidine-1-carboxylate 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 138647-52-6 4-(4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1082659-96-8 4-(4-fluorophenyl) tetrahydro pyridine hydrochloride 
• 352-13-6 4-flourophenylmagnesium bromide 
• 41979-39-9 4-piperidone hydrochloride 
• 163631-02-5 1-benzyl-4-(4-fluorophenyl)-4-hydroxypiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 462-06-6 fluorobenzene 

Downstream Products

• 374901-76-5 cis- and trans-(E)-4-(4-fluorophenyl)-1-(4-phenyl-4-{[3,5-bis(trifluoromethyl)phenyl]-prop-1-enyl}cyclohexyl)piperidine 

Relevant articles and documents

VMAT INHIBITORY COMPOUNDS

Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

1-[(1-methyl-1 H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis

A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY

Compounds of (I), or stereoisomers or pharmaceutically acceptable salts thereof, where W, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.